<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01499004</url>
  </required_header>
  <id_info>
    <org_study_id>A3921131</org_study_id>
    <nct_id>NCT01499004</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Open Label, Partial Crossover Study To Evaluate The Pharmacokinetics (PK) And Safety Of Three Modified Release (MR) And One Immediate Release (IR) Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore the drug behavior and safety following a single dose of three
      different 22 milligram tofacitinib (CP-690,550) modified-release formulations in 30 healthy
      volunteers. These formulations will be compared to 10 milligram tofacitinib (CP-690-550) in
      an immediate-release formulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCinf: Area under the plasma concentration-time profile from time 0 exprapolated to infinite time</measure>
    <time_frame>72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast: Area under the plasma concentration-time profile from time 0 to the last with quantifiable concentration</measure>
    <time_frame>72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum plasma concentration of tofacitinib (CP-690,550)</measure>
    <time_frame>72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Amount of time tofacitinib (CP-690,550) is at maximum plasma concentration</measure>
    <time_frame>72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2: The time required for one half of the total amount of tofacitinib (CP-690,550) to be removed from the plasma</measure>
    <time_frame>72 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frel: Relative bioavailability (Frel) of tofacitinib (CP-690,550) in the modified-release formulations compared to the immediate release formulation</measure>
    <time_frame>24 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tofacitinib (CP-690,550) modified-release formulation A-Fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tofacitinib (CP-690,550) modified-release formulation B1-Fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tofacitinib (CP-690,550) modified-release formulation A-Fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tofacitinib (CP-690,550) modified-release formulation B1-Fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tofacitinib (CP-690,550) modified-release formulation B2-Fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tofacitinib (CP-690,550) immediate-release formulation-Fasted</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tofacitinib (CP-690,550) modified-release formulation A</intervention_name>
    <description>A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered with food.</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tofacitinib (CP-690,550) modified-release formulation B1</intervention_name>
    <description>A single dose of 22 mg tofacitinib (CP-690,550) MR-B1 formulation administered with food</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tofacitinib (CP-690,550) modified-release formulation A</intervention_name>
    <description>A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered without food</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tofacitinib (CP-690,550) modified-release formulation B1</intervention_name>
    <description>A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B1 administered without food</description>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tofacitinib (CP-690,550) modified-release formulation B2</intervention_name>
    <description>A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B2 administered without food</description>
    <arm_group_label>Treatment E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tofacitinib (CP-690,550) immediate-release formulation</intervention_name>
    <description>A single dose of 10 mg tofacitinib (CP-690,550) immediate-release formulation administered without food</description>
    <arm_group_label>Treatment F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects and/or healthy females subjects who are of non-childbearing
             potential.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease;

          -  Clinically significant infections within the past 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>188770</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921131&amp;StudyName=A%20Phase%201%20Study%20To%20Evaluate%20The%20Pharmacokinetics%20And%20Safety%20Of%20Three%20Modified%20Release%20And%20One%20Immediate%20Release%20Formulations%20Of%20Tofaci</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2011</study_first_submitted>
  <study_first_submitted_qc>December 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2011</study_first_posted>
  <last_update_submitted>January 11, 2012</last_update_submitted>
  <last_update_submitted_qc>January 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tofacitinib</keyword>
  <keyword>CP-690</keyword>
  <keyword>550</keyword>
  <keyword>relative bioavailability</keyword>
  <keyword>modified release</keyword>
  <keyword>Phase 1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

